Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients With Ischemic Heart Failure: A Randomized Clinical Trial Publisher



Karimian B1 ; Soleimani A1 ; Mohammadsharifi G2 ; Heshmatghahdarijani K3 ; Rejali L4 ; Shafie D3 ; Amerizadeh A5 ; Sadeghi M5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Chamran Cardiovascular Medical and Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Orthopedics, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Biochemistry, Islamic Azad University, Falavarjan Branch, Isfahan, Iran
  5. 5. Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Cardiology Research and Practice Published:2022


Abstract

Aim. This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function. Methods. Fifty patients with ischemic HF with a reduced ejection fraction (HFrEF) were randomly assigned to one of two groups: the lycopene group which received 25 mg lycopene tablets once a day for 8 weeks and the control group which received placebo tablets containing starch once a day for 8 weeks. Results. Our results showed that after two months, the amount of triglyceride (TG) and FMD improved significantly compared to the control, TG decreased (219.27 vs. 234.24), and the mean of FMD increased (5.68 vs. 2.95). Other variables, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP), showed no improvement. Also, only SBP and FMD showed intragroup improvement in the intervention group. In the intervention group, only SBP and FMD exhibited intragroup improvement. Conclusions. It can be concluded that supplementing with lycopene can enhance endothelial function and reduce the TG levels in ischemic HFrEF patients. However, it had no positive effect on BP, TC, LDL-C, or HDL-C. Trial Registration. This clinical trial was registered at the Iranian Registry of Clinical Trials with IRCT registration number: IRCT20210614051574N4. © 2022 Bahareh Karimian et al.
Experts (# of related papers)
Other Related Docs
11. Changes in Lipid Profile of Patients Referred to a Cardiac Rehabilitation Program, European Journal of Preventive Cardiology (2008)
13. Vitamin D Supplementation Effects in Patients With Heart Failure, Journal of Isfahan Medical School (2010)
19. Effect of Cardiac Rehabilitation on Lipid Profile, Journal of Association of Physicians of India (2003)
23. Long Term Effects of Oral Vitamin E Supplement in Type Ii Diabetic Patients, International Journal for Vitamin and Nutrition Research (2005)
28. Anethum Graveolens and Hyperlipidemia: A Randomized Clinical Trial, Journal of Research in Medical Sciences (2014)
30. Functional Food and Cardiovascular Disease Prevention and Treatment: A Review, Journal of the American College of Nutrition (2018)
32. Effect of Flaxseed on Blood Lipid Level in Hyperlipidemic Patients, Reviews on Recent Clinical Trials (2015)
39. Vitamin E Can Reduce Blood Pressure in Mild Hypertensives, International Journal for Vitamin and Nutrition Research (2002)
45. Oral Carnitine Supplementation for Dyslipidemia in Chronic Hemodialysis Patients., Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia (2012)